Introduction
============

Syndecans are transmembrane proteoglycans that are found on the surface of many types of mammalian cells. The four syndecans in mammals are encoded by four genes, but invertebrates have just one syndecan. Based on chromosomal localization and exon organization studies, all syndecans arise from a single ancestral gene. Syndecans are expressed in a development-, cell-type-, and tissue-specific manner and function either as independent or co-receptors that mediate cell signaling ([@B14]; [@B70]). In these type I transmembrane glycoproteins, the core protein ranges in size from 20 to 45 kDa. Syndecan core proteins include an extracellular domain (ectodomain) that carries either heparan sulfate only or heparan sulfate and chondroitin sulfate a single transmembrane (TM) domain; and a short cytoplasmic domain (**Figure [1A](#F1){ref-type="fig"}**). The ectodomain can interact with a wide variety of molecules, including growth factors, cytokines, proteinases, adhesion receptors, and ECM components. Syndecan-1 is mainly expressed in mesenchymal and epithelial cells. Syndecan-2 is highly expressed in endothelial and mesenchymal tissues and in liver, neural, and fibroblast cells. Syndecan-3, the longest of the four syndecans, is expressed in neural tissue and developing musculoskeletal system, but is undetectable in epithelial cells. Finally, syndecan-4, which has the shortest core protein, is widely expressed.

![**(A)** The syndecan family of heparan sulfate proteoglycans. Syndecans consist of a transmembrane core protein with a short cytoplasmic tail and an ectodomain. All syndecan ectodomains are modified with either heparan sulfate only or heparan sulfate and chondroitin sulfate sugar chains. **(B)** A schematic showing the syndecan domains and examples of functions and interacting partners. **(C)** List of known PDZ-containing proteins that interact with syndecans.](fphar-07-00010-g001){#F1}

Syndecans are implicated in the control of cell--cell, cell--pathogen, and cell--matrix interactions via the recruitment of the actin cytoskeleton, as well as in cellular proliferation, differentiation, and migration. Syndecans can be found in cell protrusions and focal adhesions, where they colocalize with actin ([@B33]; [@B12]). Importantly, they can act as co-receptors of other cell surface receptors like growth factor receptors and integrins ([@B68]; [@B25]; [@B79]). In this context, syndecans can bind, immobilize, concentrate, and induce conformational changes in growth factors, adhesion molecules, and other signaling molecules via their heparan sulfate chains, thus facilitating their receptor interaction. They can also protect ligands from activation or sequester them away from membrane receptors ([@B106]; [@B1]).

Syndecans undergo regulated physiological shedding of their extracellular domain, a process that may be increased in pathological conditions, thereby allowing them to act as soluble effectors and/or antagonists ([@B50]; [@B63]). In addition, syntenins/syndecans, in conjunction with the syntenin-binding protein ALIX, are likely to be involved in or to enhance exosome production ([@B7]; [@B30]).

Syndecans and Cancer
====================

Syndecans are involved in cancers, infectious diseases, obesity, wound healing, and angiogenesis. As documented in recent reviews, they are considered key regulators of tumor progression ([@B9]; [@B26]; [@B92]). In some cancers, syndecan expression may regulate tumor cell function and serve as a prognostic marker for tumor progression and patient survival. Syndecan-1 expression is dysregulated in a number of cancers, including head and neck, ovarian, breast, and colorectal carcinomas ([@B91]). Syndecan-1 acts as a tumor suppressor in MDA-MB-231 breast cancer cells ([@B40]). Treating these cells with syndecan-1 small interfering RNA not only enhances β1-integrin and focal adhesion kinase activity, leading to increased cellular adhesion and migration, but it also improves cellular resistance to irradiation. A study on pre-invasive breast cancer revealed an inverse correlation between the expression of syndecan-1 and the pro-metastatic microRNA miR-10b, suggesting a potential novel mode of post-transcriptional regulation of syndecan-1 ([@B37]). Studies revealing the negative regulation of syndecan-1 by miR-10b and its pro-invasive consequences in human breast cancer cells, reported syndecan-1 as a new regulatory target of miR-10b ([@B44]). Other studies revealed that syndecan-1 decreases cell migration in lung epithelium via activation of Rap1, which slows focal adhesion disassembly ([@B2]). Syndecan-1 also plays a role in squamous cell carcinoma collagen-mediated motility and invasion by modulating RhoA and Rac activity, suggesting that decreased syndecan-1 expression during carcinoma progression may enhance tumor cell invasiveness ([@B45]).

The presence of syndecan-1 is associated with favorable outcomes in both lung cancer and mesothelioma ([@B54]; [@B3]), and the loss of syndecan-1 is a feature of hepatocellular carcinoma with high metastatic potential ([@B65]). Low syndecan-1 expression correlates with gastric carcinoma invasion and metastasis ([@B22]). In contrast, studies have reported that high expression levels of syndecan-1 in breast carcinoma are associated with high histological grade, high mitotic count, large tumor size, c-erbB-2 over-expression, and estrogen receptor-negative status. These studies show that high syndecan-1 expression correlates with the most invasive breast carcinomas ([@B86]; [@B8]; [@B57]; [@B58]). Studies using an *in vitro* breast cancer model also suggest that syndecan-1 participates directly in tumor cell spreading and adhesion ([@B11]). In prostate cancer, high syndecan-1 expression is a feature of biologically aggressive progression ([@B104]). As stated in recent comprehensive reviews, stromal expression of syndecan-1 may have negative prognostic value, and elevated serum levels of the shed syndecan ectodomain might also be a prognostic indicator ([@B32]; [@B90]). Studies have revealed a mechanism by which syndecan-1 and -4 ectodomains, may capture and induce autophosphorylation of the tyrosine kinase receptors HER2 and EGFR respectively, leading to integrin mediated carcinoma cell migration ([@B97], [@B98]).

Nuclear localization of syndecan-1 has been reported, suggesting that it may function as a transcription factor and therefore impact gene regulation affecting cancer pathogenesis ([@B15]). In addition, heparanase and syndecan-1 may cooperate to drive growth factor signaling and to regulate cell behavior, thus enhancing tumor growth and dissemination ([@B78]; [@B74]; [@B80]). One study found that syndecan-4 inhibited breast carcinoma cell invasion ([@B11]), and its expression in human breast carcinoma was described as being associated with good prognosis ([@B58]). In contrast, another study found that syndecan-4 expression correlated significantly with high histological grade and negative estrogen receptor status ([@B6]) and was therefore a marker of poorer prognosis. Furthermore, a study of pancreatic cancer showed that syndecan-2 was involved in perineural invasion of pancreatic adenocarcinoma cells ([@B28]). Silencing syndecan-2 expression in these cells significantly reduced motility and invasiveness. Syndecan-2 is upregulated in breast tumors ([@B59]) and in colon carcinomas ([@B75]; [@B83]; [@B20]). In highly metastatic colorectal cancer cells, syndecan-2 expression is enhanced by fibronectin secreted by stromal cells ([@B94]). In colorectal carcinoma, low epithelial expression of syndecan-1 is associated with a higher histological grade, with more advanced clinical stage of the patients, and with potentially more unfavorable prognosis ([@B62]; [@B39]; [@B66]). Results from a recent meta-analysis of colorectal cancer studies demonstrated that loss of syndecan-1 expression in colorectal cancer correlates with histological grade and tumor stage, but not with lymph node or distant metastasis ([@B100]). The authors also reported that syndecan-1 expression does not have prognostic value in colorectal carcinoma patients. To date, syndecan-3 has not been implicated in cancer. Although the mechanisms are not yet fully understood, these examples highlight the important role of syndecans in tumor progression and suggest that they are relevant and promising therapeutic targets ([@B78]; [@B9]; [@B92]). For instance, the anti-tumoral activity of zoledronic acid on breast cancer cells was reported to correlate with a differential modulation of syndecans ([@B27]). Synstatin peptides based on HER2 and EGFR interaction motifs on syndecan-1 and -4 respectively can competitively displace receptor tyrosine kinase interaction and disrupt activation of cell motility ([@B98]). Similar peptides were designed to block IGF1R binding to syndecan-1/αvβ3 integrin complex and inhibit the integrin activity in endothelial and tumor cells ([@B79]).

The Transmembrane Domain-Induced Oligomerization Properties of Syndecans
========================================================================

Syndecans transmembrane domain is composed of 25 hydrophobic amino acid residues responsible for the molecular interaction that causes homo-oligomerization of syndecan core proteins ([@B4]; [@B19]), a step essential for their signaling activation. The conserved GXXXG (where X is any amino acid) motif is involved in this process. Recent studies have revealed the potential of syndecan-2 and -4 to form hetero-oligomers, reducing each syndecan activity ([@B21]). This hetero-oligomerization capacity may offer insight into an underlying modulating mechanism ([@B55]).

The cytoplasmic tail has two conserved regions, C1 and C2, that share common characteristics in all syndecans, plus a central variable region (V) that may regulate cell spreading and actin cytoskeleton assembly (**Figure [1B](#F1){ref-type="fig"}**; [@B17]; [@B18]; [@B87]). Each region can support signaling complexes formation ([@B16]; [@B13]; [@B103]). The C1 domain is thought to participate in syndecan dimerization ([@B71]) and in the binding of various intracellular proteins, such as ezrin ([@B34]). In neuroblastoma, the C1 region of syndecan-3 interacts with a protein complex composed of Src family kinases and the actin-binding proteins cortactin and tubulin ([@B51]). Likewise, the V region of syndecan-4 interacts with PKCα (protein kinase Cα) as well as with phosphatidylinositol 4,5-bisphosphate (PtdIns-4,5-P2) ([@B71], [@B72]). The C2 carboxyl-terminal tetrapeptide sequence present in all syndecans consists of the highly conserved tetrapeptide sequence Glu-Phe-Tyr-Ala (EFYA) ([@B10]; [@B70]; [@B82]).

The Interactions of Syndecans with Cytoskeleton PDZ Domain Proteins
===================================================================

The EFYA sequence binds to PDZ domain-containing proteins, such as syntenin-1 ([@B36]) and CASK ([@B23]), which may function as membrane scaffold proteins that recruit signaling and cytoskeletal proteins to the plasma membrane. The EFYA motif thus belongs to the large family of PDZ-binding motifs (PDZ-BMs). Recent work suggests that PDZ interactions are involved in protein trafficking, possibly routing proteoglycans to the cell surface ([@B99]).

There is growing interest in understanding the binding of syndecans to their PDZ domain-containing counterparts (**Figure [1C](#F1){ref-type="fig"}**). Not only are the interactions involved in cytoskeletal rearrangements in response to the signaling activities, but syndecan-PDZ domain-containing protein complexes may also participate in cell-ECM adhesion and migration. For example, synectin binding to syndecan-4 may modulate in vitro cell migration ([@B31]; [@B93]). As well, cell adhesion to fibronectin is regulated by the interaction of syndecan-1 with the PDZ domain of the T-cell lymphoma invasion and metastasis gene 1 protein (Tiam1) ([@B85]). A study of hippocampal neurons revealed that syndecan-2 induces spine formation by recruiting intracellular vesicles toward postsynaptic sites through an interaction with synbindin ([@B29]).

The name PDZ is an acronym derived from the first three proteins in which these domains were identified: PSD-95 (*postsynaptic density PSD-95/SAP90*), DLG (*Drosophila melanogaster tumor suppressor septate junction protein* Disks large-1), and ZO-1 (*epithelial tight junction protein* Zonula Occludens-1) ([@B49]; [@B105]; [@B102]). Over 250 non-redundant PDZ domains have been identified in the human proteome ([@B96]) and are found in proteins involved in diverse cellular functions, such as maintenance of cell polarity, signal transduction in neurons, and cell migration ([@B38]; [@B84]; [@B46]).

The number of amino acid residues in a PDZ domain is relatively small (80--100 amino acids) ([@B43]). Structural analysis of these domains indicates that a canonical PDZ domain consists of five or six β-strands and two or three α-helices ([@B61]) (**Figure [2A](#F2){ref-type="fig"}**). In addition, the domain itself folds into a compact globular shape; this maintains the proximity of the N- and C-termini to each other on opposite sides of the PDZ-BM interaction site ([@B84]; [@B46]; [@B56]). The PDZ-BM fits in the groove between the α2-helix and the β2-strand structure such that the α2-helix is anti-parallel to the β2-strand (**Figure [2B](#F2){ref-type="fig"}**). This interaction site is also known as the carboxylate-binding site because of the highly conserved carboxylate-binding loop at the end of the groove that connects the β1- and β2-strand structures: R/K-X-X-X-G-Φ-G-Φ (where Φ is a hydrophobic residue) ([@B84]; [@B43]; [@B56]).

![**(A)** Structural definition of syndecan binding to the PDZ domain. Ribbon diagram of the syntenin PDZ2 bound to the syndecan-4 peptide TNEFYA (pdb code 1 OBY, [@B47]), **(B)** Surface charge (blue positive and red negative) representation of the PDZ2 domain with syndecan-4 (magenta) peptide displayed as ball-and-stick. **(C)** Similar representation of PDZ2 with a model of syndecan-1 tyrosine phosphorylated peptide (yellow) showed as ball-and-stick. **(D)** Phosphorylation of Tyr and Ser residues within syndecan cytoplasmic tails and their effects on PDZ protein binding: (-) no interaction; (+) interaction; (++) enhanced interaction. The conserved (C1 and C2) and variable (V) domain organization is from [@B26].](fphar-07-00010-g002){#F2}

There are no reports of PDZ domains interacting with syndecans through motifs other than the EFYA sequence. Since the EFYA motif is the only PDZ-BM in syndecans, it seems likely that all four syndecans have similar binding affinity for the same PDZ-containing proteins. For example, all syndecans have similar affinity for the PDZ1-PDZ2 tandem domain of syntenin-1 ([@B35]). However, CASK has a higher affinity for syndecan-2 and syndecan-4 than for syndecan-1 and syndecan-3. The molecular mechanism underlying this difference in affinities is unknown. On the other hand, the PDZ domain of Tiam1 binds to a peptide corresponding to the last eight residues of syndecan-1 and -3, but not to those of syndecan-2 and -4 ([@B60]).

PDZ domain-containing proteins play essential roles in most aspects of cellular homoeostasis and are implicated in diverse aspects of tumor development and metastasis ([@B88]). A number of studies have established that MDA-9/syntenin has a pivotal role in cancer development and progression, and suggest that it could be a tumor marker ([@B76]). Recent data indicate that in addition to its involvement in the migration and growth of tumor cells, syntenin appears to be involved in controlling the plasma membrane localization of active β1-integrin ([@B48]). A recent study showed that co-upregulation of CASK and syndecan-2 in colorectal cancer is associated with an unfavorable prognosis ([@B101]), suggesting that CASK could be a prognostic factor for colorectal cancer metastasis. Synbindin was shown to contribute to the aggressiveness of gastric cancer by activating the ERK signaling pathway ([@B52]), while synectin was shown to participate in pancreatic cancer growth ([@B69]). As a guanine exchange factor for Rac1, tiam1 involvement in cancer biology may be linked to its pivotal function in cytoskeletal dynamics ([@B95]). One study reported that syndecan-2 regulates colon carcinoma cell migration through Tiam1-dependent Rac activation ([@B20]).

Regulation of PDZ Binding by Phosphorylation of the Syndecan Cytoplasmic Tail
=============================================================================

The phosphorylation of Ser, Thr, or Tyr residues in the syndecan cytoplasmic tail appears to be a key mechanism that regulates its interactions with PDZ domains (**Figure [2B](#F2){ref-type="fig"}**). We reported that the formation of membrane protrusions in cells plated on immobilized laminin α3 chain LG45 domain required the dephosphorylation of tyrosine residues in the cytoplasmic tail of syndecan-1 ([@B89]; [@B81]). Further experiments demonstrated that phosphorylation of the Tyr residue in its EFYA sequence abolished its interaction with syntenin-1 (**Figure [2C](#F2){ref-type="fig"}**, [@B89]). In contrast, phosphorylation of this Tyr residue did not affect the binding of the PDZ domain of Tiam1 (**Figure [2D](#F2){ref-type="fig"}**, [@B85]; [@B60]). It is not known whether this holds true for phosphorylated syndecan-3 as well. Based on the examination of other syndecan-binding PDZ domains, the PDZ domains of CASK and synectin are predicted to interact with Tyr-phosphorylated syndecan-1 in a manner similar to that seen in the Tiam1 PDZ-phosphorylated syndecan-1 complex. This mechanism may support syndecan signaling specificity ([@B60]).

Other regulatory mechanisms involving the phosphorylation of a Ser residue in the carboxyl terminus of PDZ-binding proteins may either disrupts or enhances interactions with PDZ domains (**Figure [2D](#F2){ref-type="fig"}**, [@B24]; [@B64]; [@B41]). Studies of syndecan-4 revealed that phosphorylation of the Ser residue in the C1 region induces a conformational change in the C2 domain, even though the phosphorylation site is 20 residues away and impedes the PDZ binding ability of syntenin-1 ([@B42]; [@B53]). Furthermore, phosphorylation of the Tyr residue of the syndecan-4 C1 region was shown to enhance syntenin-1 binding and to function as a molecular switch to regulate specific integrin recycling and coordinate focal adhesion dynamics ([@B67]).

These findings reinforce the importance of residues upstream of the EFYA motif in the regulation of PDZ domain interactions with syndecans. To date, there are no reports of the phosphorylation of Thr residues in terms of regulation of syndecan binding to PDZ domains. The phosphorylation of Tyr versus Ser residues depends upon which enzymes are involved. For example, Src family kinases and Elk kinases are widely reported to be the enzymes responsible for the phosphorylation of the Tyr residues ([@B5]; [@B67]). In contrast, PKCs are the only enzymes that have been reported to be involved in Ser residue phosphorylation ([@B77]; [@B71]; [@B53]). Moreover, PKC can only recognize the Ser residue in syndecan-2 and syndecan-3, but not those in syndecan-1 and syndecan-4 ([@B77]). Similarly, endogenously phosphorylated Tyr residues were only found on syndecan-1 and sydecan-4 in B82 fibroblasts, although this cell line also expresses syndecan-2 ([@B73]).

Since phosphorylation is a key mechanism in modulating the interactions of syndecans with cytoplasmic proteins, the process is expected to be tightly regulated and some proportion of syndecans in a cell are expected to be in a phosphorylated state. Indeed, studies have found endogenously phosphorylated syndecans in cultured cells ([@B5]; [@B73]; [@B10]; [@B67]). These results illustrate the high level of complexity underlying the syndecans "turn on and off" signals.

Conclusion
==========

The study of both the structural and biological aspects of the mechanisms underlying PDZ protein binding to syndecans is an exciting field of research. Due to their high level of complexity, the physiological significance of these interactions is not yet fully clarified; however, ongoing and future work will undoubtedly shed light on these important molecular complexes and their roles in cytoplasmic signaling pathways.
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ECM

:   extracellular matrix

GAG

:   glycosaminoglycan

IGF1R

:   insulin-like growth factor-1 receptor

PDZ

:   postsynaptic density-95/disc large protein/zonula occludens-1

PDZ-BM

:   PDZ binding motif

PKC

:   protein kinase C
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